Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Shares Outstanding for 6 consecutive years, with $93.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 3.22% to $93.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.5 million, a 3.22% increase, with the full-year FY2024 number at $92.4 million, up 4.44% from a year prior.
  • Shares Outstanding was $93.5 million for Q3 2025 at Caribou Biosciences, roughly flat from $93.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $93.5 million in Q3 2025 to a low of $10.3 million in Q1 2021.
  • A 5-year average of $70.2 million and a median of $66.1 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 569.17% in 2021, then increased 1.04% in 2023.
  • Caribou Biosciences' Shares Outstanding stood at $60.3 million in 2021, then grew by 1.27% to $61.0 million in 2022, then surged by 44.93% to $88.4 million in 2023, then increased by 4.44% to $92.4 million in 2024, then rose by 1.18% to $93.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Shares Outstanding are $93.5 million (Q3 2025), $93.1 million (Q2 2025), and $93.0 million (Q1 2025).